Minireview: Challenges and opportunities in development of ppar agonists

Molecular Endocrinology

Volumn 28, Issue 11, 2014, Pages 1756-1768

  Wright, Matthew B ^a   Bortolini, Michele ^a   Tadayyon, Moh ^b   Bopst, Martin ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b MEDITECH MEDIA LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALEGLITAZAR; APOLIPOPROTEIN A1; CHIGLITAZAR; CIGLITAZONE; CYCLIN DEPENDENT KINASE 5; DARGLITAZONE; FARGLITAZAR; FENOFIBRIC ACID; GFT 505; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INT 131; ION CHANNEL; LOW DENSITY LIPOPROTEIN; MK 0533; MURAGLITAZAR; NUCLEAR RECEPTOR COREPRESSOR; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROTEIN KINASE; RETINOID X RECEPTOR; ROSIGLITAZONE; SAROGLITAZAR; STEROID RECEPTOR COACTIVATOR 1; TESAGLITAZAR; TRIACYLGLYCEROL; TROGLITAZONE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; LIGNAN;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CONFORMATIONAL TRANSITION; DRUG MECHANISM; DRUG SAFETY; EDEMA; FATTY ACID OXIDATION; GENE EXPRESSION; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; WEIGHT GAIN; AGONISTS; ANIMAL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS;

ANIMALS; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; LIGNANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; THIAZOLIDINEDIONES;

EID: 84908341464     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2013-1427     Document Type: Article

References (130)

1. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta: US Department of Health and Human Services; 2011.
2. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35:556-564.
3. Leiter LA, Fitchett DH, Gilbert RE, et al. Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary). Can J Cardiol. 2011;27:124-131.
4. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287:2570-2581.
5. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371:1800-1809.
6. Lalloyer F, Staels B. Fibrates, glitazones, and peroxisome prolif-erator-activated receptors. Arterioscler Thromb Vasc Biol. 2010; 30:894-899.
7. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011;1812: 1007-1022.
8. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004;351: 1106-1118.
9. Kahn SE, Haffner SM, Viberti G, et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2010;33:177-183.
10. Panigrahy D, Shen L, Kieran MW, Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Exp Opin Invest Drugs. 2003;12:1925-1937.
11. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-7 ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383-389.
12. Yuan Z, Liu Y, Liu Y, et al. Peroxisome proliferation-activated receptor-7 ligands ameliorate experimental autoimmune myocarditis. Cardiovasc Res. 2003;59:685-694.
13. Bright JJ, Natarajan C, Muthian G, Barak Y, Evans RM. Peroxisome proliferator-activated receptor-7-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol. 2003; 171:5743-5750.
14. Pancani T, Phelps JT, Searcy JL, et al. Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-7 agonists in cultured hippocampal neurons. J Neurochem. 2009;109: 1800-1811.
15. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7,2003. Circulation. 2003;108:2941-2948.
16. Betteridge DJ. Thiazolidinediones and fracture risk in patients with type 2 diabetes. Diabet Med. 2011;28:759-771.
17. ® (muraglitazar, BMS-298,585). Bethesda, MD: Food and Drug Administration; 2005.
18. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298: 1180-1188.
19. Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevalu-ation of cardiovascular outcomes in the RECORD trial. Am Heart J. 2013;166:240-249.
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
21. Friedland SN, Leong A, Filion KB, et al. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med. 2012;125:126-133.
22. Scheen AJ. Thiazolidinediones and liver toxicity. Diabetes Metab. 2001;27:305-313.
23. Conlon D. Goodbye glitazars? Br J Diabetes Vasc Dis. 2006;6: 135-137.
24. Matthews L, Berry A, Tersigni M, D’Acquisto F, Ianaro A, Ray D. Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology. 2009;150:75-86.
25. Mieczkowska A, Basle MF, Chappard D, Mabilleau G. Thiazolidinedione induced osteocyte apoptosis by a GPR40-dependent mechanism. J Biol Chem. 2012;287:23517–23526.
26. Morrison A, Yan X, Tong C, Li J. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt and JNK signalling in nondiabetic mice. Am J Physiol. 2011;301:H895-H902.
27. Jeong I, Choi BH, Hahn SJ. Rosiglitazone inhibits Kv4.3 potassium channels by open-channel block and acceleration of closed-state inactivation. Br J Pharmacol. 2011;163:510-520.
28. Paddock ML, Wiley SE, Axelrod HL, et al. MitoNEET is a uniquely folded 2Fe-2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci USA. 2007;104: 14342-14347.
29. Colca JR, McDonald WG, Waldon DJ, et al. Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab. 2004;286:E252-E260.
30. Colca JR, VanderLugt JT, Adams WJ, et al. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin Pharmacol Ther. 2013;93:352-359.
31. Colca JR, McDonald WG, Cavey GS, et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)—relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One. 2013;8:e61551.
32. Staels B, Maes M, Zambon A. Fibrates and future PPARa agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med. 2008;5:542-553.
33. Kota BP, Huang THW, Roufgalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res. 2005;51:85-94.
34. Li D, Chen K, Sinha N, et al. The effects of PPAR-7 ligand piogli-tazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res. 2005;65:907-912.
35. Lonard DM, O’Malley BW. Nuclear receptor coregulators: modulators of pathology and therapeutic targets. Nat Rev Endocrinol. 2012;8:598-604.
36. Mukherjee R, Sun S, Santomenna L, et al. Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. J Steroid Biochem Mol Biol. 2002;81:217-225.
37. Guan HP, Ishizuka T, Chui PC, Lehrke M, Lazar MA. Corepres-sors selectively control the transcriptional activity of PPAR 7 in adipocytes. Genes Dev. 2005;19:453-461.
38. Kodera Y, Takeyama K, Murayama A, Suzawa M, Masuhiro Y, Kato S. Ligand type-specific interactions of peroxisome prolifera-tor-activated receptor 7 with transcriptional coactivators. J Biol Chem. 2000;275:33201-33204.
39. Shao G, Heyman RA, Schulman IG. Three amino acids specify coactivator choice by retinoid X receptors. Mol Endocrinol. 2000; 14:1198-1209.
40. Rocchi S, Auwerx J. Peroxisome proliferator-activated receptor 7, the ultimate liaison between fat and transcription. Br J Nutr 2000; 84(suppl 2):S223-S227.
41. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 1998;92:829-839.
42. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferator-activated receptor-7 by troglitazone and rosigli-tazone. Diabetes. 2000;49:539-547.
43. Weidner C, de Groot JC, Prasad A, et al. Amorfrutins are potent antidiabetic dietary natural products. Proc Natl Acad Sci USA. 2012;109:7257-7262.
44. Zhang F, Lavan BE, Gregoire FM. Selective modulators of PPAR-7 activity: molecular aspects related to obesity and side effects. PPAR Res. 2007;2007:32696.
45. Pickavance L, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JPH. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol. 1999;128:1570-1576.
46. Motani A, Wang Z, Weiszmann J, et al. INT131: a selective modulator of PPAR 7. J Mol Biol. 2009;386:1301-1311.
47. DePaoli A, Higgins LS. INT131, a non-TZD selective PPAR7 modulator (SPPARM), does not cause toxicities typical of TZD full PPAR7 agonists following 6-month high dose treatment of rats or monkeys. Diabetologia. 2008;51:S369 (Abstract).
48. Dunn FL, Higgins LS, Fredrickson J, DePaoli AM. Selective modulation of PPAR7 activity can lower plasma glucose without typical thiazolidinedione side effects in patients with type 2 diabetes. J Diabetes Complications. 2011;25:151-158.
49. Pickavance L, Widdowson PS, King P, Ishii S, Tanaka H, Williams G. The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC-555 treatment. Br J Pharmacol. 1998;125:767-770.
50. Choi J, Park Y, Lee HS, Yang Y, Yoon S. 1,3-Diphenyl-1H-pyra-zole derivatives as a new series of potent PPAR7 partial agonists. Bioorg Med Chem. 2010;18:8315-8323.
51. Guo L, Zhang L, Sun Y, et al. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR 7 agonists on rat primary hepatocytes and human HepG2 cells. Mol Divers. 2006; 10:349-360.
52. Rogue A, Lambert C, Josse R, et al. Comparative gene expression profiles induced by PPAR7 and PPAR a/7 agonists in human hepatocytes. PLoS One. 2011;6:e18816.
53. Deehan R, Maerz-Weiss P, Catlett NL, et al. Comparative transcriptional network modeling of three PPAR-a/7 co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes. PLoS One. 2012;7:e35012.
54. Liu C, Lin JD. PGC-1 coactivators in the control of energy metabolism. Acta Biochim Biophys Sin (Shanghai). 2011;43:248-257.
55. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-a/y agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374:126-135.
56. Ruilope LM, Hanefeld M, Lincoff AM, et al. Effects of aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes. J Am Soc Nephrol. 2012;23:9B.
57. Lincoff AM, Tardif JC, Schwartz GG, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014;311(15):1515-1525.
58. Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor 7 (PPAR7): Is the genomic activity the only answer? Steroids. 2010;75:585-594.
59. Camp HS, Tafuri SR. Regulation of peroxisome proliferator-activated receptor 7 activity by mitogen-activated protein kinase. J Biol Chem. 1997;272:10811-10816.
60. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogen-esis through MAP kinase-mediated phosphorylation of PPAR7. Science. 1996;274:2100-2103.
61. Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR7by Cdk5. Nature. 2010; 466:451-456.
62. Ember Therapeutics. Our Science. Watertown, MA: Ember Therapeutics; 2013. Available at: http://www.embertx.com/approach.php.
63. Burgermeister E, Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPAR7. Cell Cycle. 2007;6:1539-1548.
64. Burgermeister E, Friedrich T, Hitkova I, et al. The Ras inhibitors caveolin-1 and docking protein 1 activate peroxisome proliferator-activated receptor 7 through spatial relocalization at helix 7 of its ligand-binding domain. Mol Cell Biol. 2011;31:3497-3510.
65. Reginato MJ, Bailey ST, Krakow SL, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor-activating properties. J Biol Chem. 1998;273:32679-32684.
66. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors and are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406-3410.
67. Zuris JA, Harir Y, Conlan AR, et al. Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-accep-tor protein. Proc Natl Acad Sci USA. 2011;108:13047-13052.
68. Kusminski CM, Holland WL, Sun K, et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med. 2012;18:1539-1549.
69. Wiley SE, Murphy AN, Ross SA, van der Geer P, Dixon JE. MitoNEET is an iron-containing outer mitochondrial membrane protein that regulates oxidative capacity. Proc Natl Acad Sci USA. 2007;104:5318-5323.
70. Bricker DK, Taylor EB, Schell JC, et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science. 2012;337:96-100.
71. Herzig S, Raemy E, Montessuit S, et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science. 2012;337:93-96.
72. Divakaruni AS, Murphy AN. Cell biology. A mitochondrial mystery, solved. Science. 2012;337:41-43.
73. Gilde AJ, Van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiol Scand. 2003;178:425-434.
74. Khandoudi N, Delerive P, Berrebi-Bertrand I, Buckingham RE, Staels B, Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-, inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfu-sion injury. Diabetes. 2002;51:1507-1514.
75. Sidell RJ, Cole MA, Draper NJ, Desrois M, Buckingham RE, Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker Fatty rat heart. Diabetes. 2002;51:1110-1117.
76. Edgley AJ, Thalén PG, Dahllöf B, Lanne B, Ljung B, Oakes ND. PPAR 7 agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats. Eur J Pharmacol. 2006;538:195-206.
77. Okada M, Yan SF, Pinsky DJ. Peroxisome proliferator-activated receptor-7 activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J. 2002;16:1861-1868.
78. Magri CJ, Fava S. Albuminuria and glomerular filtration rate in type 2 diabetes mellitus. Minerva Urol Nefrol. 2011;63:273-280.
79. Biscetti F, Pola R. Endothelial progenitor cells and angiogenesis join the PPAR-7. Circ Res. 2008;103:7-9.
80. Wang N, Yang G, Jia Z, et al. Vascular PPAR-7 controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab. 2008;8:482-491.
81. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 1997;46:433-439.
82. Yue T-L, Chen J, Bao W, et al. In vivo myocardial protection from ischemia/reperfusion injury by the PPAR-7 agonist rosiglitazone. Circulation. 2001;104:2588-2594.
83. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation. 2000;101:1165-1171.
84. Xu Y, Gen M, Lu L, et al. PPAR-7 activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol. 2005;288:H1314-H1323.
85. Lu L, Reiter MJ, Xu Y, Chicco A, Greyson CR, Schwartz GG. Thiazolidinedione drugs block cardiac KATP channels and may increase propensity for ischaemic ventricular fibrillation in pigs. Diabetologia. 2008;51:675-685.
86. Szentandrássy N, Harmati G, Bárándi L, et al. Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells. Br J Pharmacol. 2011;163:499-509.
87. Ohshima K, Mogi M, Horiuchi M. Role of peroxisome proliferator-activated receptor-7 in vascular inflammation. IntJ Vasc Med. 2012;2012:508416.
88. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidin-ediones: an assessment from bench to bedside. Kidney Int. 2006; 70:1223-1233.
89. Jiang C, Ting AT, Seed B. PPAR-7 agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82-86.
90. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-7 is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
91. Padilla J, Leung E, Phipps RP. Human B lymphocytes and B lymphomas express PPAR-7 and are killed by PPAR-7 agonists. Clin Immunol. 2002;103:22-33.
92. Harris SG, Phipps RP. The nuclear receptor PPAR 7 is expressed by mouse T lymphocytes and PPAR 7 agonists induce apoptosis. Eur J Immunology. 2001;31:1098-1105.
93. Zhang X, Rodriguez-Galán MC, Subleski JJ, et al. Peroxisome proliferator-activated receptor-7 and its ligands attenuate biologic functions of human natural killer cells. Blood. 2004;104:3276-3284.
94. Yang J, Zhou Y, Guan Y. PPAR7 as a therapeutic target in diabetic nephropathy and other renal diseases. Curr Opin Nephrol Hyper-tens. 2012;21:97–105.
95. Natarajan C, Bright JJ. Peroxisome proliferator-activated receptor-7 agonists inhibit experimental allergic encephalomyelitis by blocking IL-12 production, IL-12 signaling and Th1 differentiation. Genes Immun. 2002;3:59-70.
96. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evan RM. PPAR-7 dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 2001; 7:48-52.
97. Aoki T. Current status of carcinogenicity assessment of PPAR agonists by the US FDA and a mode-of-action approach to the carcinogenic potential. J Toxicol Pathol. 2007;20:197-202.
98. Tannehill-Gregg SH, Sanderson TP, Minnema D, et al. Rodent carcinogenicity profile of the antidiabetic dual PPAR a and 7 agonist muraglitazar. Toxicol Sci. 2007;98:258-270.
99. Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a 7-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol. 2008;36:218-231.
100. Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleks-iewicz MB. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers. 2005;10:295-309.
101. Bortolini M, Wright MB, Bopst M, Balas B. Examining the safety of PPAR agonists—current trends and future prospects. Expert Opin Drug Saf. 2013;12:65-79.
102. Pruimboom-Brees IM, Francone O, Pettersen JC, et al. The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude. Toxicol Pathol. 2012;40:810-818.
103. Chaffer CL, Thomas DM, Thompson EW, Williams ED. PPAR-7-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer. 2006;6:53.
104. Panigrahy D, Huang S, Kieran MW, Kaipainen A. PPAR-7 as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther. 2005;4:687-693.
105. Elstner E, Müller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptor-7 and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998;95:8806-8811.
106. Kubota T, Koshizuka K, Williamson EA, et al. Ligand for peroxisome proliferator-activated receptor 7 (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344-3352.
107. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor 7 in human prostate cancer. Proc Natl Acad Sci USA. 2000;97:10990-10995.
108. Hisatake JI, Ikezoe T, Carey M, Holden S, Tomoyasu S, Koeffler HP. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor 7 in human prostate cancer. Cancer Res. 2000;60:5494-5498.
109. Xu Y, Iyengar S, Roberts RL, Shappell SB, Peehl DM. Primary culture model of peroxisome proliferator-activated receptor 7 activity in prostate cancer cells. J Cell Physiol. 2003;196:131-143.
110. Grommes C, Landreth GE, Schlegel U, Heneka MT. The nonthia-zolidinedione tyrosine-based peroxisome proliferator-activated receptor ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells. J Pharmacol Exp Ther. 2005;313:806-813.
111. Grommes C, Landreth GE, Sastre M, et al. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor agonist treatment. Mol Pharmacol. 2006;70:1524-1533.
112. Seufert S, Coras R, Trankle C, et al. PPAR-7 activators: off-target against glioma cell migration and brain invasion. PPAR Res. 2008;2008:513943.
113. Wei S, Yang J, Lee SL, Kulp SK, Chen CS. PPAR7-independent antitumor effects of thiazolidinediones. Cancer Lett. 2009;276: 119-124.
114. Wick M, Hurteau G, Dessev C, et al. PPAR-7 is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-in-dependent inhibition of lung cancer cell growth. Mol Pharmacol. 2002;62:1207-1214.
115. Bren-Mattison Y, Meyer AM, Van Putten V, et al. Antitumori-genic effects of PPAR-7 in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor k-B. Mol Pharmacol. 2008;73:709-717.
116. Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Dia-betologia. 2010;54:280-290.
117. Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83:835-839.
118. Yang W, Rachez C, Freedman LP. Discrete roles for peroxisome proliferator-activated receptor 7 and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol. 2000;20: 8008-8017.
119. Picard F, Gehin M, Annicotte J, et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell. 2002;111:931-941.
120. Li PP, Shan S, Chen YT, et al. The PPARa/7 dual agonist chigli-tazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol. 2006;148:610-618.
121. Acton JJ III, Akiyama TE, Chang CH, et al. Discovery of (2R)-2-(3-{3-[(4-methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor 7 modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume. J Med Chem. 2009;52:3846-3854.
122. Larsen PJ, Lykkegaard E, Larsen LK, Fleckner J, Sauerberg P, Was-sermann K, Wulff EM. Dissociation of antihyperglycemic and adverse effects of partial PPAR-7 agonist balaglitzone. Eur J Pharmacol. 2008;596:173-179.
123. Feldman P, Lambert MH, Henke BR. PPAR modulators and PPAR pan agonists for metabolic diseases: the next generation of drugs targeting peroxisome proliferator-activated receptors? Curr Topics Med Chem. 2008;8:728-749.
124. Agrawal R. The first approved agent in the glitazar’s class: saro-glitazar. Curr Drug Targets. 2014;15:151-155.
125. Jain MR, Giri S, Sundar R, Swain P, Ranvir R. ZYH1, a novel PPAR agonist that shows lipid-lowering and insulin-sensitizing effects with good safety profile in preclinical models. Diabetes. 2012;61(1):269.
126. Genfit. The FDA grants fast track designation to GFT505 in NASH Reuters. Cambridge, MA: Genfit; 2014. Available at: http://www.genfit.com/wp-content/uploads/2014/03/2014.02.17_PR-GENFIT_ EN.pdf. Accessed February 17, 2014.
127. Colca JR, Kletzien RF. What has prevented the expansion of insulin sensitisers? Exp Opin Invest Drugs. 2006;15:205-210.
128. Dietz M, Mohr P, Kuhn B, et al. Comparative molecular profiling of the PPARa/7 activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem. 2012;7:1101-1111.
129. Nevin DK, Lloyd DG, Fayne D. Rational targeting of peroxisome proliferating activated receptor subtypes. Curr Med Chem. 2011; 18:5598-5623.
130. Cariou B, Zair Y, Staels B, Bruckert E. Effects of the new dual PPARa/S agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. Diabetes Care. 2011;34:2008-2014.